Person

Paul R. Kirchgraber

Formerly CEO, Covance Drug Development, Labcorp

Current S&P 500 boards
0
Current roles
0
Open-market buys
$0
Open-market sales
$3.9M

Current roles

From Section 16 filings (Forms 3, 4 and 5) in the last 13 months.

No current S&P 500 role.

Past roles

“Last filing” is the latest Form 3/4/5 for that company, an upper bound on the end date.

  • LH
    Labcorp
    CEO, Covance Drug Development
    Nov 2019 – last filing May 2023

Sits alongside

People who currently share a board or management team with this person.

No current colleagues on record.

Open-market trades

Purchases and sales reported on Form 4 at S&P 500 companies.

DateCompanyTypeSharesPriceValue
May 19, 2023LHSale4,300$216.91$933K
Feb 21, 2023LHSale8,000$250.58$2.0M
May 6, 2021LHSale2,500$276.55$691K
Nov 4, 2020LHSale1,500$214.14$321K

SEC reporting-owner ID (CIK) 1791393 · all filings on EDGAR

Paul R. Kirchgraber | USBoard